As companies make progress with generative AI, they are increasingly capturing and delivering value. Specific examples in 2024 include Lilly, Sanofi, Pfizer, Roche, Boehringer Ingelheim, Novo Nordisk and aiCure). Generative AI has the potential to revolutionize the pharma and biotech industry. By applying this technology to specific use cases, organizations can achieve significant improvements in efficiency and effectiveness.

Key Areas of Impact

Medical Affairs, Commercial, and Market Access

• Automated content generation (e.g., literature summaries, medical abstracts, presentations, marketing materials, training curricula including personalized questions)
• Enhanced knowledge management and information retrieval
• Personalized customer engagement and insights

Clinical Development and Regulatory

• Accelerated clinical trial design and execution, including training of clinical monitors, study personnel
• Streamlined regulatory submissions and approvals, semi-automated document preparation, with human oversight and ownership
• Advanced data analysis and insights, for example accelerated patient-level summaries based on study reports

Pharmacovigilance and Risk Management

• Improved safety monitoring and signal detection
• Automated literature summaries and reports
• Enhanced risk assessment and mitigation strategies

To realize the benefits of private generative AI, organizations benefit from adopting a strategic approach, focusing on well-defined use cases and measurable outcomes. By prioritizing and selecting use cases with a short-term return on investment and low implementation effort, the more effective organizations facilitate change and accelerate the adoption of generative AI. This allows them to increase the organizational agility and increase their operating margin.